Cannabidiol inhibits pathogenic T cells, decreases spinal microglial activation and ameliorates multiple sclerosis-like disease in C57BL/6 mice

British Journal of Pharmacology

Volumn 163, Issue 7, 2011, Pages 1507-1519

  Kozela, Ewa ^a   Lev, Nirit ^a   Kaushansky, Nathali ^b   Eilam, Raya ^c   Rimmerman, Neta ^d   Levy, Rivka ^d   Ben Nun, Avraham ^b   Juknat, Ana ^a   Vogel, Zvi ^a,d  

^a TEL AVIV UNIVERSITY   (Israel)

^b Immunology Department   (Israel)

^c Histology Department   (Israel)

^d WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

cannabidiol; cannabinoids; EAE; microglia; MOG; T cells

Indexed keywords

CANNABIDIOL; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; MYELIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; CELL PROTEIN; GALECTIN 3; PROTEIN MAC 2; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; AXONAL INJURY; CELL ACTIVATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MICROGLIA; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; ONSET AGE; PRIORITY JOURNAL; SPINAL CORD NERVE CELL; T LYMPHOCYTE; ANTIPROLIFERATIVE ACTIVITY; CD3+ T LYMPHOCYTE; CELLULAR DISTRIBUTION; DOWN REGULATION; IMMUNOHISTOCHEMISTRY; LYMPHOCYTIC INFILTRATION; MACROPHAGE ACTIVATION; MOUSE STRAIN; NERVE CELL LESION; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; TREATMENT DURATION;

ANIMALS; CANNABIDIOL; DIFFUSE AXONAL INJURY; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; MACROPHAGES; MICE; MICE, INBRED C57BL; MICROGLIA; MULTIPLE SCLEROSIS; MYELIN PROTEINS; NERVE DEGENERATION; SPINAL CORD; T-LYMPHOCYTES;

EID: 79960293903     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01379.x     Document Type: Article

References (63)

1. Alexander SPH, Mathie A, Peters JA, (2009). Guide to Receptors and Channels (GRAC), 4th edn. Br J Pharmacol 158: S1-S254.
2. Arévalo-Martín A, Vela JM, Molina-Holgado E, Borrell J, Guaza C, (2003). Therapeutic action of cannabinoids in a murine model of multiple sclerosis. J Neurosci 23: 2511-2516. (Pubitemid 36418583)
3. Bayewitch M, Avidor-Reiss T, Levy R, Barg J, Mechoulam R, Vogel Z, (1995). The peripheral cannabinoid receptor: adenylate cyclase inhibition and G protein coupling. FEBS Lett 375: 143-147.
4. Bennett JL, Stüve O, (2009). Update on inflammation, neurodegeneration, and immunoregulation in multiple sclerosis: therapeutic implications. Clin Neuropharmacol 32: 121-132.
5. Ben-Nun A, Lando Z, (1983). Detection of autoimmune cells proliferating to myelin basic protein and selection of T cell lines that mediate experimental autoimmune encephalomyelitis (EAE) in mice. J Immunol 130: 1205-1209. (Pubitemid 13159853)
6. Buckley NE, McCoy KL, Mezey E, Bonner T, Zimmer A, Felder CC, et al,. (2000). Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor. Eur J Pharmacol 396: 141-149. (Pubitemid 30265571)
7. 1 receptor participation. Adv Exp Med Biol 493: 207-214. (Pubitemid 34020229)
8. Compston A, Coles A, (2008). Multiple sclerosis. Lancet 372: 1502-1517.
9. Consroe P, Laguna J, Allender J, Snider S, Stern L, Sandyk R, et al,. (1991). Controlled clinical trial of cannabidiol in Huntington's disease. Pharmacol Biochem Behav 40: 701-708.
10. Croxford JL, Miller SD, (2003). Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R+WIN55,212. J Clin Invest 111: 1231-1240. (Pubitemid 36519940)
11. Croxford JL, Yamamura T, (2005). Cannabinoids and the immune system: potential for the treatment of inflammatory diseases? J Neuroimmunol 166: 3-18. (Pubitemid 41074652)
12. Croxford JL, Pryce G, Jackson SJ, Ledent C, Giovannoni G, Pertwee RG, et al,. (2008). Cannabinoid-mediated neuroprotection, not immunosuppression, may be more relevant to multiple sclerosis. J Neuroimmunol 193: 120-129.
13. Cunha JM, Carlini EA, Pereira AE, Ramos OL, Pimentel C, Gagliardi R, et al,. (1980). Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology 21: 175-185. (Pubitemid 10039764)
14. Dirikoc S, Priola SA, Marella M, Zsürger N, Chabry J, (2007). Nonpsychoactive cannabidiol prevents prion accumulation and protects neurons against prion toxicity. J Neurosci 27: 9537-9544. (Pubitemid 47492190)
15. El-Remessy AB, Al-Shabrawey M, Khalifa Y, Tsai NT, Caldwell RB, Liou GI, (2006). Neuroprotective and blood-retinal barrier-preserving effects of cannabidiol in experimental diabetes. Am J Pathol 168: 235-244. (Pubitemid 43062576)
16. Esposito G, Scuderi C, Savani C, Steardo L Jr, De Filippis D, Cottone P, et al,. (2007). Cannabidiol in vivo blunts β-amyloid induced neuroinflammation by suppressing IL-1 β and iNOS expression. Br J Pharmacol 151: 1272-1279. (Pubitemid 47255904)
17. Gallily R, Even-Chena T, Katzavian G, Lehmann D, Dagan A, Mechoulam R, (2003). γ-irradiation enhances apoptosis induced by cannabidiol, a non-psychotropic cannabinoid, in cultured HL-60 myeloblastic leukemia cells. Leuk Lymphoma 44: 1767-1773. (Pubitemid 37221053)
18. Hampson AJ, Grimaldi M, Axelrod J, Wink D, (1998). Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci U S A 95: 8268-8273. (Pubitemid 28326102)
19. Hanisch UK, Kettenmann H, (2007). Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci 10: 1387-1394. (Pubitemid 350014685)
20. Heppner FL, Greter M, Marino D, Falsig J, Raivich G, Hovelmeyer N, et al,. (2005). Experimental autoimmune encephalomyelitis repressed by microglial paralysis. Nat Med 11: 146-152. (Pubitemid 40321349)
21. Huitinga I, Van Rooijen N, De Groot CJ, Uitdehaag BM, Dijkstra CD, (1990). Suppression of experimental allergic encephalomyelitis in Lewis rats after elimination of macrophages. J Exp Med 172: 1025-1033. (Pubitemid 20343201)
22. Ignatowska-Jankowska B, Jankowski M, Glac W, Swiergel AH, (2009). Cannabidiol-induced lymphopenia does not involve NKT and NK cells. J Physiol Pharmacol 3 (Suppl.): 99-103.
23. Iuvone T, Esposito G, Esposito R, Santamaria R, Di Rosa M, Izzo AA, (2004). Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on β-amyloid-induced toxicity in PC12 cells. J Neurochem 89: 134-141. (Pubitemid 38420682)
24. Jack C, Ruffini F, Bar-Or A, Antel JP, (2005). Microglia and multiple sclerosis. J Neurosci Res 81: 363-373. (Pubitemid 41359291)
25. Jan TR, Su ST, Wu HY, Liao MH, (2007). Suppressive effects of cannabidiol on antigen-specific antibody production and functional activity of splenocytes in ovalbumin-sensitized BALB/c mice. Int Immunopharmacol 7: 773-780.
26. 2 receptors. Proc Natl Acad Sci U S A 96: 14136-14141.
27. Johnson DA, Amirahmadi S, Ward C, Fabry Z, Johnson JA, (2010). The absence of the pro-antioxidant transcription factor Nrf2 exacerbates experimental autoimmune encephalomyelitis. Toxicol Sci 114: 237-246.
28. Jones JL, Coles AJ, (2010). New treatment strategies in multiple sclerosis. Exp Neurol 225: 34-39.
29. Juknat A, Pietr M, Kozela E, Rimmerman N, Levy R, Coppola G, et al,. (2011). Differential transcriptional profiles mediated by exposure to the cannabinoids cannabidiol and Δ9-tetrahydrocannabinol in BV-2 microglial cells. Br J Pharm DOI: 10.1111/j.1476-5381.2011.01461.x.
30. Kaplan BL, Rockwell CE, Kaminski NE, (2003). Evidence for cannabinoid receptor-dependent and -independent mechanisms of action in leukocytes. J Pharmacol Exp Ther 306: 1077-1085. (Pubitemid 37025316)
31. Kaplan BL, Springs AE, Kaminski NE, (2008). The profile of immune modulation by cannabidiol (CBD) involves deregulation of nuclear factor of activated T cells (NFAT). Biochem Pharmacol 76: 726-737.
32. Kaushansky N, Zhong MC, Kerlero de Rosbo N, Hoeftberger R, Lassmann H, Ben-Nun A, (2006). Epitope specificity of autoreactive T and B cells associated with experimental autoimmune encephalomyelitis and optic neuritis induced by oligodendrocyte-specific protein in SJL/J mice. J Immunol 177: 7364-7376. (Pubitemid 44715107)
33. Klein TW, Newton CA, (2007). Therapeutic potential of cannabinoid-based drugs. Adv Exp Med Biol 601: 395-413.
34. Kobayashi M, Yamamoto M, (2005). Molecular mechanisms activating the Nrf2-Keap1 pathway of antioxidant gene regulation. Antioxid Redox Signal 7: 385-394. (Pubitemid 40279806)
35. Koning N, Uitdehaag BM, Huitinga I, Hoek RM, (2009). Restoring immune suppression in the multiple sclerosis brain. Prog Neurobiol 89: 359-368.
36. Kozela E, Pietr M, Juknat A, Rimmerman N, Levy R, Vogel Z, (2010). Cannabinoids Delta(9)-tetrahydrocannabinol and cannabidiol differentially inhibit the lipopolysaccharide-activated NF-kappaB and interferon- β/STAT proinflammatory pathways in BV-2 microglial cells. J Biol Chem 285: 1616-1626.
37. Lastres-Becker I, Molina-Holgado F, Ramos JA, Mechoulam R, Fernández-Ruiz J, (2005). Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease. Neurobiol Dis 19: 96-107. (Pubitemid 40544727)
38. Lee CY, Wey SP, Liao MH, Hsu WL, Wu HY, Jan TR, (2008). A comparative study on cannabidiol-induced apoptosis in murine thymocytes and EL-4 thymoma cells. Int Immunopharmacol 8: 732-740.
39. Lev N, Barhum Y, Melamed E, Offen D, (2004). Bax-ablation attenuates experimental autoimmune encephalomyelitis in mice. Neurosci Lett 359: 139-142. (Pubitemid 38446657)
40. Liou GI, Auchampach JA, Hillard CJ, Zhu G, Yousufzai B, Mian S, et al,. (2008). Mediation of cannabidiol anti-inflammation in the retina by equilibrative nucleoside transporter and A2A adenosine receptor. Invest Ophthalmol Vis Sci 49: 5526-5531.
41. Lyman WD, Sonett JR, Brosnan CF, Elkin R, Bornstein MB, (1989). Delta 9-tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis. J Neuroimmunol 23: 73-81. (Pubitemid 19125801)
42. McHugh D, Hu SS, Rimmerman N, Juknat A, Vogel Z, Walker JM, et al,. (2010). N-arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptor. BMC Neurosci 11: 44.
43. McKallip RJ, Jia W, Schlomer J, Warren JW, Nagarkatti PS, Nagarkatti M, (2006). Cannabidiol-induced apoptosis in human leukemia cells: a novel role of cannabidiol in the regulation of p22phox and nox4 expression. Mol Pharmacol 70: 897-908. (Pubitemid 44268447)
44. Mackie K, (2005). Distribution of cannabinoid receptors in the central and peripheral nervous system. Handb Exp Pharmacol 168: 299-325.
45. Malfait AM, Gallily R, Sumariwalla PF, Malik AS, Andreakos E, Mechoulam R, et al,. (2000). The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci U S A 97: 9561-9566. (Pubitemid 30650815)
46. 2 receptor in microglial cells in response to inflammatory stimuli. J Neurochem 95: 437-445. (Pubitemid 41457512)
47. Maresz K, Pryce G, Ponomarev ED, Marsicano G, Croxford JL, Shriver LP, et al,. (2007). Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. Nat Med 13: 492-497. (Pubitemid 46559830)
48. Mechoulam R, Peters M, Murillo-Rodriguez E, Hanus LO, (2007). Cannabidiol-recent advances. Chem Biodivers 4: 1678-1692.
49. Nahas GG, Morishima A, Desoize B, (1977). Effects of cannabinoids on macromolecular synthesis and replication of cultured lymphocytes. Fed Proc 36: 1748-1752. (Pubitemid 8078416)
50. Pietr M, Kozela E, Levy R, Rimmerman N, Lin YH, Stella N, et al,. (2009). Differential changes in GPR55 during microglial cell activation. FEBS Lett 583: 2071-2076.
51. Ponomarev ED, Shriver LP, Maresz K, Dittel BN, (2005). Microglial cell activation and proliferation precedes the onset of CNS autoimmunity. J Neurosci Res 81: 374-389. (Pubitemid 41359292)
52. Puffenbarger RA, Boothe AC, Cabral GA, (2000). Cannabinoids inhibit LPS-inducible cytokine mRNA expression in rat microglial cells. Glia 29: 58-69. (Pubitemid 30031134)
53. Rajesh M, Pan H, Mukhopadhyay P, Ba' tkai S, Osei-Hyiaman D, Hasko G, et al,. (2007). Cannabidiol attenuates high glucose-induced endothelial cell inflammatory response and barrier disruption. J Leukoc Biol 82: 1382-1389.
54. Reichert F, Rotshenker S, (1999). Galectin-3/MAC-2 in experimental allergic encephalomyelitis. Exp Neurol 160: 508-514.
55. Rieder SA, Chauhan A, Singh U, Nagarkatti M, Nagarkatti P, (2010). Cannabinoid-induced apoptosis in immune cells as a pathway to immunosuppression. Immunobiology 215: 598-560.
56. Shevach EM, (1999). Animal models for autoimmune and inflammatory disease. In:, Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM, Strober W, (eds). Current Protocols in Immunology. John Wiley & Sons, Inc: New York, pp. 15.0.1-15.0.5.
57. 2): identification of cannabinoid receptor subtype selective ligands. J Pharmacol Exp Ther 278: 989-999. (Pubitemid 27166944)
58. Tanasescu R, Constantinescu CS, (2010). Cannabinoids and the immune system: an overview. Immunobiology 215: 588-597.
59. Walter L, Franklin A, Witting A, Wade C, Xie Y, Kunos G, et al,. (2003). Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J Neurosci 23: 1398-1405. (Pubitemid 36258918)
60. Weiss L, Zeira M, Reich S, Slavin S, Raz I, Mechoulam R, et al,. (2008). Cannabidiol arrests onset of autoimmune diabetes in NOD mice. Neuropharmacology 54: 244-249. (Pubitemid 350299408)
61. Wu HY, Chu RM, Wang CC, Lee CY, Lin SH, Jan TR, (2008). Cannabidiol-induced apoptosis in primary lymphocytes is associated with oxidative stress-dependent activation of caspase-8. Toxicol Appl Pharmacol 226: 260-270.
62. Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, et al,. (2003). Cannabinoids for treatment of spasticity and others symptoms related to multiple sclerosis (CAMS study): multicenter randomized placebo-controlled trial. Lancet 362: 1517-1526. (Pubitemid 37410189)
63. Zuardi AW, (2008). Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Rev Bras Psiquiatr 30: 271-280.